PMGC Holdings Inc. (ELAB) - Dilution Analysis

8-K filing: The Company entered into a securities purchase agreement with an investor for an equity line of credit of up to $40,000,000, including an initial pre-paid purchase, issuing shares of common stock, and entered into a Pledge Agreement and Guaranties with its subsidiaries. ($20.0M proceeds)

10-K filing | 1.2M shares outstanding

8-K filing: Stock split 1-for-4 | Outstanding: 744,121 → 186,030

10-Q filing | 0.7M shares outstanding

8-K filing: PMGC Holdings Inc. entered into a Securities Purchase Agreement for an equity line of credit with an institutional investor, involving the issuance of shares of common stock. ($4.55M proceeds)

8-K filing: Stock split 3.5-for-1 | Outstanding: 1,375,385 → 392,947

10-Q filing | 1.4M shares outstanding

S-1/A filing: This S-1/A filing relates to the offer and sale of up to 559,261 shares of common stock issuable upon the exercise of certain Common Stock Purchase Warrants.

10-K filing | 0.7M shares outstanding

8-K filing: PMGC Holdings Inc. consummated a registered direct offering on March 24, 2025, selling 129,145 shares of common stock and pre-funded warrants to purchase 165,305 shares, resulting in net proceeds of approximately $1,245,305.76 for general corporate purposes and potential acquisitions. ($1.25M proceeds)

8-K filing: On March 18, 2025, the Company repurchased thirty shares of its common stock at a purchase price of $4.235 per Share and a warrant to purchase an aggregate of thirty-six shares of common stock at an exercise price of $4,200.00 per share at a purchase price of $0.01 for total proceeds of approximately $127.06. ($0.0M proceeds)

8-K filing: PMGC Holdings Inc. repurchased thirty two and a half common shares or thirty three common shares after an adjustment and thirty eight common shares from two existing shareholders at $0.7231 per share, totaling approximately $52.00 on March 7, 2025. ($0.0M proceeds)

8-K filing: Stock split 1-for-7 | Outstanding: 4,042,295 → 577,470

S-1 filing: This S-1 filing registers the resale of up to 969,386 shares of common stock issuable upon exercise of warrants by selling shareholders.

S-3 filing: PMGC Holdings Inc. files an S-3 to offer and sell shares of common stock, preferred stock, debt securities, rights or warrants to purchase common stock or any combination of these securities, either separately or in units, in one or more offerings with a total offering price not exceeding $100,000,000.

8-K filing: PMGC Holdings Inc. entered into a warrant inducement agreement with certain warrant holders to reduce the exercise price of existing warrants and issue new warrants to purchase 969,386 shares of common stock, with expected gross proceeds of approximately $1,938,772. ($1.94M proceeds)

8-K filing: Stock split 1-for-200 | Outstanding: 517,661,269 → 2,588,306

10-Q filing | 517.7M shares outstanding

8-K filing: Elevai Labs Inc. entered into the Second Amended and Restated Consulting Agreement for Non-Employee Chief Executive Officer with GB Capital Ltd, and the Second Amended and Restated Consulting Agreement for Non-Executive Chairman with Northstrive Companies Inc., compensating them with cash, Series B Preferred Stock, and potential milestone bonuses.

8-K filing: Elevai Labs Inc. entered into a securities purchase agreement with institutional investors for a registered direct offering, involving the sale of common stock and warrants, which closed on September 24, 2024, resulting in net proceeds of approximately $7.05 million for the Company. ($7.05M proceeds)

S-1/A filing: Elevai Labs Inc. is offering up to 28,368,794 shares of common stock, together with Series A warrants to purchase up to 28,368,794 shares of common stock and Series B warrants to purchase up to 28,368,794 shares of common stock and up to 28,368,794 Pre-Funded Warrants.

S-1/A filing: Elevai Labs Inc. is offering up to 28,368,794 shares of the Company's common stock, together with Series A warrants to purchase up to 28,368,794 shares of common stock and Series B warrants to purchase up to 28,368,794 shares of common stock.

S-1 filing: Elevai Labs Inc. is offering up to 25,000,000 shares of common stock, together with warrants, in a best efforts offering with Univest Securities, LLC as the exclusive placement agent.

10-Q filing | 18.3M shares outstanding

10-Q filing | 17.3M shares outstanding

8-K filing: Elevai Labs Inc. approved a consulting agreement with Santorio Biomedical, LLC, granting the consultant 2,450,000 shares of restricted common stock payable in four installments.

10-K filing | 17.3M shares outstanding

10-Q filing | 17.3M shares outstanding

S-1/A filing: This is an S-1/A filing about indemnification of directors and officers.

S-1/A filing: The filing discusses indemnification of directors and officers and limitation of liability as permitted by Delaware law. It also mentions the company maintains insurance policies for its directors and officers.

S-1 filing: Elevai Labs, Inc. is offering 1,500,000 shares of common stock in an initial public offering, with an expected price range of $4.00 to $6.00 per share, and has granted a 45-day option to the underwriter to purchase up to additional 225,000 shares of Common Stock.